{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:52:07Z","timestamp":1791525127352,"version":"4.3.4"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis (anti-MDA5+ DM) spans pulmonary states from no detectable interstitial lung disease (ILD) to rapidly progressive ILD (RP-ILD). We mapped molecular programs and prediction evidence to determine how recurrent biological states may support dynamic stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Web of Science, Ovid and Embase were searched from inception to 22 August 2026. Two reviewers independently screened records and extracted data. Reporting followed PRISMA-ScR; evidence was synthesized across molecular and prediction domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 4, 166 records, 2, 317 remained after deduplication, 349 underwent full-text assessment, and 95 sources (80 primary studies and 15 syntheses) were included. Type I\/III interferon signaling was the most reproducible program. Myeloid inflammatory-remodeling, adaptive activation with lymphocyte or natural-killer-cell loss, vascular-coagulation injury, and immunometabolic disturbance formed additional overlapping axes aligned with pulmonary-state transitions. Clinical and radiomic models showed strong short-term discrimination; harmonized landmarks, calibration, geographic validation, and decision-timed molecular sampling would strengthen clinical use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The evidence supports an integrated map linking recurrent molecular programs to dynamic pulmonary risk. A calibrated clinical\u2013imaging backbone, augmented by parsimonious molecular modules with incremental value and updated at prespecified landmarks, offers a practical framework for prospective endotype validation and treatment-aware prediction in anti-MDA5+ DM-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/doi.org\/10.37766\/inplasy2026.10.0018<\/jats:ext-link>\n                      , identifier INPLASY2026100018.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1979138","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:34:49Z","timestamp":1791524089000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Candidate molecular endotypes and dynamic risk prediction in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a systematic scoping review"],"prefix":"10.3389","volume":"17","author":[{"given":"Zhiwei","family":"Zuo","sequence":"first","affiliation":[{"name":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Yang","sequence":"additional","affiliation":[{"name":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbin","family":"Li","sequence":"additional","affiliation":[{"name":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renhe","family":"Li","sequence":"additional","affiliation":[{"name":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11926-025-01188-7","article-title":"Anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis: recent progress in pathophysiology and treatment","volume":"27","author":"Yoshida","year":"2025","journal-title":"Curr Rheumatol Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel","year":"2021","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12016-020-08822-5","article-title":"Interstitial lung disease in anti-MDA5 positive dermatomyositis","volume":"60","author":"Wu","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.55563\/clinexprheumatol\/9s7djz","article-title":"Different phenotypic manifestations between Brazilian and Japanese anti-MDA5 antibody-positive dermatomyositis: an international tricentric longitudinal study","volume":"43","author":"Faria","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003150","article-title":"Clinical, radiological and pathological features of anti-MDA5 antibody-associated interstitial lung disease","volume":"9","author":"Chen","year":"2023","journal-title":"RMD Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00267-4","article-title":"Idiopathic inflammatory myopathies related lung disease in adults","volume":"13","author":"Sehgal","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152231","article-title":"Risk factors for mortality in patients with anti-MDA5 antibody-positive dermatomyositis: a meta-analysis and systematic review","volume":"62","author":"Xie","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1628748","article-title":"Risk factors for mortality in anti-MDA5 antibody-positive dermatomyositis with interstitial lung disease: a systematic review and meta-analysis","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keag311","article-title":"Predictors of rapidly progressive interstitial lung disease in anti-MDA5 dermatomyositis: a meta-analysis","volume":"65","author":"Liu","year":"2026","journal-title":"Rheumatol (Oxford)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24726","article-title":"Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease","volume":"36","author":"Li","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic","volume":"33","author":"Ballman","year":"2015","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/art.34657","article-title":"Brief report: association of HLA-DRB1*01:01\/*04:05 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population","volume":"64","author":"Gono","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212149","article-title":"Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis","volume":"77","author":"Kochi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11752","article-title":"Comprehensive enteroviral serology links infection and anti-melanoma differentiation-associated protein 5 dermatomyositis","volume":"7","author":"Jayaraman","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1151695","article-title":"Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients","volume":"14","author":"Qian","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6458","DOI":"10.1038\/s41467-022-34145-4","article-title":"Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications","volume":"13","author":"Ye","year":"2022","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-023-03243-z","article-title":"Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis","volume":"26","author":"Qiu","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115769","article-title":"Tryptophan metabolism alteration is associated with rapidly progressive interstitial lung disease of anti-MDA5+ dermatomyositis","volume":"168","author":"Liu","year":"2026","journal-title":"Int Immunopharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/art.42308","article-title":"Identification of three different phenotypes in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease","volume":"75","author":"Xu","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1286973","article-title":"Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2196\/62836","article-title":"Mortality risk prediction in patients with antimelanoma differentiation-associated, gene 5 antibody-positive, dermatomyositis-associated interstitial lung disease: algorithm development and validation","volume":"27","author":"Li","year":"2025","journal-title":"J Med Internet Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12931-024-02843-w","article-title":"Radiomics based on HRCT can predict RP-ILD and mortality in anti-MDA5\u2009+\u2009dermatomyositis patients: a multi-center retrospective study","volume":"25","author":"He","year":"2024","journal-title":"Respir Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1565803","article-title":"Anti-MDA5+ dermatomyositis following SARS-COV-2 infections: a systematic review","volume":"16","author":"Lattarulo","year":"2025","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1649489","article-title":"When viral infections meet the anti-MDA5 antibody-positive dermatomyositis","volume":"16","author":"Liu","year":"2026","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1796496","article-title":"Influencing factors for rapidly progressive interstitial lung disease in patients with anti-MDA5 antibody-positive dermatomyositis: a systematic review and meta-analysis","volume":"17","author":"Li","year":"2026","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1567833","article-title":"The role of monocytes and macrophages in idiopathic inflammatory myopathies: insights into pathogenesis and potential targets","volume":"16","author":"Izuka","year":"2025","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1652211","article-title":"Multi-omics-driven biomarker discovery in autoimmune diseases: a comprehensive review","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1804598","article-title":"Applications of artificial intelligence in systemic lupus erythematosus: integrating multi-omics data for precision medicine","volume":"17","author":"Biswas","year":"2026","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1893602","article-title":"Multi-omics integration in autoimmune encephalitis: from novel biomarker discovery to precision therapeutic strategies","volume":"17","author":"Chen","year":"2026","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/g4l70r","article-title":"Anti-MDA5-positive dermatomyositis and remission in a single referral centre population","volume":"41","author":"Tiniakou","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/joim.13607","article-title":"Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis","volume":"293","author":"Jin","year":"2023","journal-title":"J Intern Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/df2oc3","article-title":"Anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis exhibit three clinical phenotypes with different prognoses","volume":"40","author":"Yang","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/qumg88","article-title":"Peripheral blood immunophenotypic diversity in patients with anti-MDA5+ dermatomyositis and its impact on prognosis","volume":"44","author":"Zhang","year":"2026","journal-title":"Clin Exp Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1349611","article-title":"Disease-associated immune cell endotypes in anti-MDA5-positive dermatomyositis using unbiased hierarchical clustering","volume":"15","author":"Guo","year":"2024","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae303","article-title":"From machine learning to clinical practice: phenotypic clusters of anti-MDA5 antibody-positive dermatomyositis","volume":"25","author":"Koopman","year":"2024","journal-title":"Brief Bioinform"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20850","article-title":"Risk stratification in anti-MDA5+ dermatomyositis-related interstitial lung disease by using cluster analysis","volume":"40","author":"He","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105136","article-title":"MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C)","volume":"104","author":"David","year":"2024","journal-title":"EBioMedicine"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1504380","article-title":"Pneumocystis jirovecii pneumonia increases the 3-months mortality of anti-MDA5-antibody-positive dermatomyositis patients","volume":"15","author":"Gao","year":"2024","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/jmpuxa","article-title":"Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study","volume":"43","author":"You","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2401488","DOI":"10.1183\/13993003.01488-2024","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","volume":"65","author":"Wu","year":"2025","journal-title":"Eur Respir J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12931-026-03572-y","article-title":"Distinct anti-MDA5 antibody trajectories associated with long-term outcomes in 6-month survivors of anti-MDA5 dermatomyositis with interstitial lung disease","volume":"27","author":"Chen","year":"2026","journal-title":"Respir Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170165","article-title":"HLA-DRB1 alleles as genetic risk factors for the development of anti-MDA5 antibodies in patients with dermatomyositis","volume":"44","author":"Chen","year":"2017","journal-title":"J Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead006","article-title":"WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease","volume":"62","author":"Guo","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.02.017","article-title":"The prospective registry of myositis (PROMIS): I. Next-generation sequencing identifies HLA-DQA1 as a novel genetic risk of anti-MDA5 antibody-positive dermatomyositis","volume":"84","author":"Yang","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s12931-025-03379-3","article-title":"Gene variants of interferon induced with helicase C domain 1 in Japanese patients with dermatomyositis-associated rapidly progressive interstitial lung disease: a genetic association study using whole-exome and Sanger sequencing","volume":"26","author":"Okamoto","year":"2025","journal-title":"Respir Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.tim.2018.08.007","article-title":"A balancing act: MDA5 in antiviral immunity and autoinflammation","volume":"27","author":"Dias Junior","year":"2019","journal-title":"Trends Microbiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.743704","article-title":"RNA-containing immune complexes formed by anti-melanoma differentiation associated gene 5 autoantibody are potent inducers of IFN-\u03b1","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102831","article-title":"Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production","volume":"130","author":"Coutant","year":"2022","journal-title":"J Autoimmun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169057","article-title":"Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1249844","article-title":"Transcriptomic profiling and longitudinal study reveal the relationship of anti-MDA5 titer and type I IFN signature in MDA5+ dermatomyositis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead117","article-title":"IFN-beta and EIF2AK2 are potential biomarkers for interstitial lung disease in anti-MDA5 positive dermatomyositis","volume":"62","author":"Liu","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/em67zx","article-title":"Potential role of type I interferon\/IP-10 axis in the pathogenesis of anti-MDA5 antibody-positive dermatomyositis","volume":"41","author":"Kokuzawa","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/art.42785","article-title":"Prognostic role of interferon-\u03bb3 in anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated interstitial lung disease","volume":"76","author":"Fukada","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"25537","DOI":"10.1038\/s41598-025-10895-1","article-title":"Dysregulated type I\/III interferon system in circulation from patients with anti-MDA5-positive dermatomyositis","volume":"15","author":"Yoshida","year":"2025","journal-title":"Sci Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.15937","article-title":"Transcriptomic signatures in different tissues of anti-MDA5 positive dermatomyositis: Uncovering genes with predictive potential for RP-ILD","author":"Xue","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"B65","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13075-026-03752-7","article-title":"Dysregulation of YTHDF2 promotes the over expression of interferon beta in anti-MDA5 antibody-positive dermatomyositis","volume":"28","author":"Zhang","year":"2026","journal-title":"Arthritis Res Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/imm.70101","article-title":"Interferon-\u03b2 triggers Z-DNA binding protein 1-mediated PANoptosis in T cells of anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis","volume":"178","author":"Zhang","year":"2026","journal-title":"Immunology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead597","article-title":"Single-cell landscape of peripheral immune response in patients with anti-melanoma differentiation-associated gene 5 dermatomyositis","volume":"63","author":"He","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13075-025-03639-z","article-title":"Single-cell sequencing reveals distinct peripheral immune responses in anti-MDA5 antibody positive dermatomyositis with rapidly progressive interstitial lung disease","volume":"27","author":"Weng","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70226","article-title":"Monocyte-macrophage dynamics as key in disparate lung and peripheral immune responses in severe anti-melanoma differentiation-associated gene 5-positive dermatomyositis-related interstitial lung disease","volume":"15","author":"Shi","year":"2025","journal-title":"Clin Transl Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1697803","article-title":"Exhaustion of NK cells and interferon activation in anti-MDA5(+) dermatomyositis are associated and determine the development of ILD","volume":"16","author":"Shao","year":"2025","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2026.01.003","article-title":"IgG from anti-MDA5+ CADM patients impairs NK cell function via CD16 in RP-ILD","volume":"288","author":"Yang","year":"2026","journal-title":"Transl Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1924385","article-title":"Reduced peripheral CD4+ memory T-cell counts mark a mortality-associated immunophenotype in anti-MDA5 dermatomyositis","volume":"17","author":"Qian","year":"2026","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac030","article-title":"Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients","volume":"61","author":"Hensgens","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S509777","article-title":"Shared and distinctive inflammation-related protein profiling in idiopathic inflammatory myopathy with\/without anti-MDA5 autoantibodies","volume":"18","author":"Zhang","year":"2025","journal-title":"J Inflammation Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.628128","article-title":"Aberrantly expressed Galectin-9 is involved in the immunopathogenesis of anti-MDA5-positive dermatomyositis-associated interstitial lung disease","volume":"9","author":"Liang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s13075-025-03676-8","article-title":"Integrated metabolomic profiling identifies citrate as novel diagnostic biomarker for anti-MDA5-positive dermatomyositis","volume":"27","author":"Li","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.08.011","article-title":"Multiomics analysis uncovers subtype-specific mechanisms and biomarkers in idiopathic inflammatory myopathies","volume":"85","author":"Xiao","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-082505","article-title":"PROBAST+AI: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"B80","doi-asserted-by":"publisher","first-page":"6134","DOI":"10.1038\/s41598-026-37104-x","article-title":"Serum interferon-\u03bb3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILD","volume":"16","author":"Kitahara","year":"2026","journal-title":"Sci Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab371","article-title":"Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease","volume":"61","author":"Gono","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.940251","article-title":"Risk prediction for rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis: The CRAFT model","volume":"29","author":"Guo","year":"2023","journal-title":"Med Sci Monit"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac094","article-title":"Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis","volume":"61","author":"So","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.04.057","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: The FLAIR model","volume":"158","author":"Lian","year":"2020","journal-title":"Chest"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/art.41566","article-title":"Risk prediction modeling based on a combination of initial serum biomarker levels in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"73","author":"Gono","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.978708","article-title":"Prediction model for the pretreatment evaluation of mortality risk in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease","volume":"13","author":"Gui","year":"2022","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.908365","article-title":"A new predictive model for the prognosis of MDA5(+) DM-ILD","volume":"9","author":"Niu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.860798","article-title":"A matrix prediction model for the 6-month mortality risk in patients with anti-melanoma differentiation-associated protein-5-positive dermatomyositis","volume":"9","author":"Ouyang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/resp.70106","article-title":"The FLATCAN model: A novel score for predicting mortality risk in anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"30","author":"Zong","year":"2025","journal-title":"Respirology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.768052","article-title":"A computed tomography radiomics-based prediction model on interstitial lung disease in anti-MDA5-positive dermatomyositis","volume":"8","author":"Xu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead263","article-title":"A nomogram based on clinical factors and CT radiomics for predicting anti-MDA5+ DM complicated by RP-ILD","volume":"63","author":"Li","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B92","doi-asserted-by":"publisher","first-page":"83","DOI":"10.21037\/qims-2025-1427","article-title":"Semiquantitative HRCT scoring: a reliable predictor of rapidly progressive interstitial lung disease in patients with anti-MDA5 positive dermatomyositis","volume":"16","author":"Zhang","year":"2026","journal-title":"Quant Imaging Med Surg"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020191145","article-title":"The image biomarker standardization initiative: Standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1148\/ryai.240300","article-title":"Checklist for artificial intelligence in medical imaging (CLAIM): 2024 update","volume":"6","author":"Tejani","year":"2024","journal-title":"Radiol Artif Intell"},{"key":"B95","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12916-019-1466-7","article-title":"Calibration: the Achilles heel of predictive analytics","volume":"17","author":"Van Calster","year":"2019","journal-title":"BMC Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220139","article-title":"Coexistence of anti-Ro52 antibodies in anti-MDA5 antibody-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk","volume":"50","author":"Lv","year":"2023","journal-title":"J Rheumatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/zmn18h","article-title":"Serum Krebs von den Lungen-6 concentrations reflect severity of anti-melanoma differentiation-associated protein 5 antibody positive dermatomyositis associated interstitial lung disease","volume":"40","author":"Zhu","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa843","article-title":"Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis","volume":"60","author":"Gui","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13154","article-title":"IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis\/dermatomyositis","volume":"289","author":"Shimizu","year":"2021","journal-title":"J Intern Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13023-024-03153-6","article-title":"Elevated serum B-cell activator factor levels predict rapid progressive interstitial lung disease in anti-melanoma differentiation associated protein 5 antibody positive dermatomyositis","volume":"19","author":"Shi","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"B103","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s13023-025-03921-y","article-title":"Anti-MDA5 antibody IgG1 subtype is associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis","volume":"20","author":"Wu","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"B104","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/rheumatology\/keac229","article-title":"Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease","volume":"62","author":"Xu","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac627","article-title":"Changes in anti-MDA5 antibody titres and serum cytokine levels before and after diagnosis of anti-MDA5 antibody-positive dermatomyositis","volume":"62","author":"Kogami","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2501802","DOI":"10.1183\/13993003.01802-2025","article-title":"Serum ferritin trajectories predict mortality risk in anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis: a longitudinal cohort study","volume":"67","author":"Zhang","year":"2026","journal-title":"Eur Respir J"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1177\/17534666241294000","article-title":"The efficacy and safety of tofacitinib in anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2024","journal-title":"Ther Adv Respir Dis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102941","article-title":"Efficacy of plasma exchange in patients with anti-MDA5 rapidly progressive interstitial lung disease","volume":"133","author":"Bay","year":"2022","journal-title":"J Autoimmun"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05530-5","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy","volume":"40","author":"Ge","year":"2021","journal-title":"Clin Rheumatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1979138\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:34:51Z","timestamp":1791524091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1979138\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":111,"alternative-id":["10.3389\/fimmu.2026.1979138"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1979138","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"1979138"}}